MedPath

Vandetanib

Generic Name
Vandetanib
Brand Names
Caprelsa
Drug Type
Small Molecule
Chemical Formula
C22H24BrFN4O2
CAS Number
443913-73-3
Unique Ingredient Identifier
YO460OQ37K
Background

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Indication

Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.

Associated Conditions
Metastatic Thyroid Gland Medullary Carcinoma, Locally advanced Medullary thyroid cancer
Clinical Trials
Related News

Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Phase 2
Terminated
Conditions
Gastric Cancer
Interventions
First Posted Date
2008-05-23
Last Posted Date
2015-01-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
8
Registration Number
NCT00683787
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma

Phase 1
Completed
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2008-05-21
Last Posted Date
2016-08-29
Lead Sponsor
Sanofi
Target Recruit Count
8
Registration Number
NCT00681798
Locations
🇨🇭

Research Site, Bellinzona, Switzerland

Study of GemOx and Vandetanib in Advanced Solid Malignancy

Phase 1
Completed
Conditions
Advanced Incurable Solid Malignancy
Interventions
First Posted Date
2008-04-17
Last Posted Date
2014-01-23
Lead Sponsor
Leonard Appleman
Target Recruit Count
22
Registration Number
NCT00660725
Locations
🇺🇸

University of Pittsburgh Cancer Institute / Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Small Cell Lung Cancer
Interventions
Drug: Placebo
First Posted Date
2008-02-13
Last Posted Date
2020-02-11
Lead Sponsor
Hoosier Cancer Research Network
Target Recruit Count
74
Registration Number
NCT00613626
Locations
🇺🇸

Helen F. Graham Cancer Center, Newark, Delaware, United States

🇺🇸

Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

🇺🇸

Cancer Care Center of Southern Indiana, Bloomington, Indiana, United States

and more 16 locations

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Phase 1
Completed
Conditions
Gliosarcoma
Glioblastoma
Interventions
First Posted Date
2008-02-12
Last Posted Date
2013-02-20
Lead Sponsor
Annick Desjardins
Target Recruit Count
49
Registration Number
NCT00613223
Locations
🇺🇸

Duke University Health System, Durham, North Carolina, United States

Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Phase 1
Withdrawn
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2008-01-28
Last Posted Date
2014-03-10
Lead Sponsor
Mayo Clinic
Registration Number
NCT00601614

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Phase 2
Terminated
Conditions
Mesothelioma
Interventions
First Posted Date
2008-01-17
Last Posted Date
2016-10-10
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
25
Registration Number
NCT00597116
Locations
🇨🇭

Research Site, Zurich, Switzerland

Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

Phase 1
Completed
Conditions
Malignant Solid Tumour
Biliary Cancer
Pancreatic Cancer
Interventions
First Posted Date
2007-10-30
Last Posted Date
2013-12-25
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
23
Registration Number
NCT00551096
Locations
🇺🇸

University of Colorado Denver, Aurora, Colorado, United States

Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Phase 2
Completed
Conditions
Thyroid Neoplasms
Interventions
Other: Placebo
First Posted Date
2007-09-28
Last Posted Date
2024-04-19
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
164
Registration Number
NCT00537095
Locations
🇨🇭

Research Site, Bern, Switzerland

Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Anal, Colon, and Rectal Cancers
Colorectal Neoplasms
Colon/Rectal Cancer
First Posted Date
2007-09-21
Last Posted Date
2012-07-16
Lead Sponsor
Branimir Sikic
Target Recruit Count
13
Registration Number
NCT00532909
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy